The REPViT brand was created in 2020 to market and commercialise an innovative diagnostic platform for both virus and bacterial infections based on Indicate Solutions' proprietary IP (EP20382499.0).
The aim of REPViT is to offer fast, affordable and easy to use diagnostic solutions for consumers and professionals to detect SARS-CoV-2, Influenza and other viruses and bacteria at home and on the go, in less than 15 minutes using saliva.
The REPViT device concept is a rapid Nucleic Acid Test (NAT) equivalent to PCR in a single-use handheld over the counter test format, similar to a pregnancy test.
The REPViT technology does not require any manufacturing that is not available at large scale (i.e. no electronics, microfluidics, optics etc), does not use enzymes and does not require large laboratory equipment or specialist staff. This allows for rapid mass production and deployment of the test to meet demand in order to contain even very virulent infections.
The REPViT technology is easy to use, not sensitive to temperature and can be prepared in a home-test kit format, applied in all geographies, and most circumstances such as work, school, transport, hospital, care home or football stadium. It can be adapted to detect additional virus based, or bacterial, infectious diseases.
Due to the simplicity of handling and application of the REPViT test, it can be sold as a B2B product to doctors and hospitals or as B2C in form of a home-test kit through chemists or pharmacies and drugstores. Its comfortable application (using saliva from spitting and without intrusive nasal or buccal swabbing) will make it the preferred test.
The low production cost of the REPViT tests allows for the test to be used by all income levels and a number of tests can be used in sequence
The REPViT platform technology is easily adapted from the initial Covid-19/Influenza test and subsequently to other infectious diseases caused by viruses and bacteria.
This will allow governments, professionals and individuals to work together effectively to contain infectious diseases more efficiently and keep infection rates low.
Founder & Chief Scientific Officer (CSO)
Charles is director of oncology research at Biodonostia Biomedical Research Centre (San Sebastián, Spain). He is also an Ikerbasque Research Professor, Marie Curie Fellow and University of Oxford Research Lecturer. A pioneer in diagnostic biomarkers in blood and other biological fluids.
Mónica Vicente (PhD)
Head of Scientific Development
Mónica studied Pharmacy at UPV, followed by a PhD in the use of nanoparticles for diagnostics and therapy.
Marco Jimenez (PhD)
Chief Technical Officer (CTO)
Marco is a physicist with a PhD in Photonics Engineering from University of Alcalá. He has spent time at CEA (Grenoble) and has significant experience in the biotech sector.
Chief Operation Officer (COO)
Javier graduated from the University of Deusto with a Psychology degree and later with a Masters in Entrepreneurship. Javier previously held a position in Tecnalia Ventures
Operation Manager (OM)
Marta obtained her first degree in Pharmacy before specializing in the Pharmaceutical Industry, including practical experience in pharmacovigilance.
Medical Scientific Liaison Manager (MSL)
Jonathan is the Medical Scientific Liaison Manager and holds a Chemistry degree as well as an official master degree in Applied Chemistry and Polymeric Materials. He has also been working in the surface engineering field and has participated in several R&D projects.
Daniel Maitland (MA)
Co-founder & IT consultant
Director at Opus Energy. With 10+ years of experience in IT and successful growth and exit in multiple companies. Founding director of Oxford Cloud Technology.
Prof. Peter J. Dobson OBE
Pete was Director of Oxford University’s Begbroke Science Park until 2013, and the Strategic Advisor on Nanotechnology to the UK Research Councils. He founded Oxonica, Oxford Biosensors and Oxford NanoSystems and has specific expertise in nanoparticles, nanostructures, optoelectronics and biosensors
María Armesto (Dphil)
Maria did her first degree and masters at the University of Oviedo. Later she obtained her doctorate (Dphil) from the University of Oxford at the institute of virology specializing on the development of new therapies for Rna viruses. Afterwards, she spent seven years as a senior scientist in IAH Compton within the coronavirus group.
Ms. Miren Isasi (MBA)
Advisor Business Development and Investor Relations
Miren holds a Dip. Economics from the London School of Economics (LSE), Advanced Macroeconomics from the LSE and an MBA from Institut d’études politiques de Paris (Sciences-Po). She worked in asset management with JP Morgan Private Bank, Dresdner Kleinwort Benson and has held numerous operative and advisory C-level positions in the Basque Country, Switzerland and the UK. She is also a member of the International Commission Alumni of MBA Sciences-Po.
Ms. Alaitz Zabala (MBA)
Alaitz obtained her MBA from Mondragon University in Spain and has a degree in Administration and Business Management specializing in Finance and Accountability from Deusto University. She has been the Financial Director at the Biodonostia Heath Research Institute since 2008 and was CFO at Viralgen Vector Core until 2020.